MG
CRDF icon

Michael Gelband’s Cardiff Oncology CRDF Stock Holding History

Michael Gelband’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-18,164
Closed -$45K – 2014
2022
Q1 		$45K Buy
18,164
+6,000
+49% +$21.2K ﹤0.01% 2070
2021
Q4 		$73K Sell
12,164
-13,297
-52% -$79.3K ﹤0.01% 1995
2021
Q3 		$170K Sell
25,461
-11,303
-31% -$71K ﹤0.01% 1817
2021
Q2 		$244K Sell
36,764
-47,488
-56% -$403K ﹤0.01% 1867
2021
Q1 		$780K Buy
84,252
+44,139
+110% +$536K 0.01% 1067
2020
Q4 		$722K Buy
+40,113
New +$705K 0.01% 1036

Other funds holding CRDF

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Michael Gelband's CRDF Position: Q2 2022 in Review

Michael Gelband sold out of Cardiff Oncology (CRDF) in Q2 2022, closing a stake of 18,164 shares — an estimated $45K sold.

Michael Gelband first reported a position in CRDF in Q4 2020 and held it in 6 quarters. The position peaked at $780K in Q1 2021. 67 funds tracked by Wall St. Rank hold CRDF as of Q2 2022.

  • Michael Gelband reported no remaining Cardiff Oncology position as of Q2 2022 after selling out during the quarter.
  • Michael Gelband sold 18,164 Cardiff Oncology shares in Q2 2022, an estimated $45K.
  • Michael Gelband first reported a position in Cardiff Oncology in Q4 2020 and held it in 6 quarters.
  • Michael Gelband's Cardiff Oncology position peaked at $780K in Q1 2021.
  • 67 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2022.

Based on ExodusPoint Capital Management's 13F filing for Q2 2022, filed 22 Aug 2022.